Andreessen Horowitz July 7, 2022
Peter Donnelly, Vineeta Agarwala and Lauren Richardson

Peter Donnelly is a professor of statistical science at the University of Oxford and the CEO of Genomics PLC, which uses large-scale human genetic data to inform healthcare and drug discovery. In this interview he, Lauren Richardson, and a16z general partner Vineeta Agarwala discuss the concept of polygenic risk scores with and how this lets us quantify how much your personal genetic configuration, as a whole, affects your risk for disease.

They explore how our deepening understanding of the genetic components of common diseases, such as diabetes, heart disease, and cancer, is helping empower a shift from ‘sick care’ to risk management and preventative medicine. But first, the conversation begins...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Interview / Q&A, Pharma / Biotech, Trends
Chinese biotech crackdown would reset U.S. drug development
Avenzo, BioAge-backer Sands Capital raises new $555M life sciences fund
Results are in from Wegovy's longest trial yet: 2 new findings
AI database to bolster research for GLP1-RAs as precision medicines
Weight loss drugs and surgery complications: New study

Share This Article